NCT03226223View on ClinicalTrials.gov

Pharmacogenetics of Naltrexone for Stimulant Abuse

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 15, 2016

Primary Completion Date

July 15, 2019

Study Completion Date

July 30, 2020

Conditions
Substance Use DisordersMethamphetamine Abuse
Interventions
DRUG

Intranasal Methamphetamine

Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER

NCT03226223 - Pharmacogenetics of Naltrexone for Stimulant Abuse | Biotech Hunter | Biotech Hunter